What botulinum toxin can do after facial nerve palsy
Facial nerve palsy can leave more than weakness. During recovery, some people develop synkinesis: an intended facial movement triggers an unwanted second movement. Closing the eye may pull the mouth, smiling may narrow the eye, or speaking may tighten the neck. Others have resting asymmetry because muscle groups on the recovering side contract too strongly, while the other side has normal activity.
Botulinum toxin temporarily reduces chemical signalling from a nerve ending to a muscle. In this setting, the practical aim is not to make the face immobile. It is to reduce selected overactivity enough that a chosen movement becomes less distorted or that resting balance improves. Targets may include muscles around the eye, mouth, chin or neck, depending on the observed pattern.
Its effects are local and temporary. It does not reconnect the facial nerve, regenerate motor units, restore a muscle that remains denervated, or establish normal movement control. It can also weaken a muscle that is contributing usefully to expression, speech, eyelid closure or oral competence. That trade-off explains why facial palsy treatment is usually more conservative and pattern-led than routine cosmetic use.
| Evidence Position | What the evidence supports | Where the claim exceeds evidence | What would change the position |
|---|---|---|---|
| Proven | Botulinum toxin causes temporary, dose-dependent weakening of injected skeletal muscle. | It cannot be described as nerve repair or a cure for facial palsy. | Not applicable to the basic pharmacological effect. |
| Plausible | Targeted weakening can reduce troublesome synkinesis and selected asymmetry. | One injection map cannot be assumed to fit every pattern of palsy. | Better comparative studies using functional and patient-reported outcomes. |
| Over-marketed | Improvement in a specific unwanted movement may be meaningful. | Claims of restoring a fully normal face, symmetry in every expression, or permanent correction are not supported. | Long-term controlled evidence showing durable functional restoration. |
Why synkinesis happens and why the pattern matters
Synkinesis commonly appears during recovery from a facial nerve injury rather than in the earliest flaccid phase. A recovering nerve may reinnervate muscles in an altered pattern, and the brain must then work with changed signals and changed muscle recruitment. The result is not merely “tightness”. It is a linked-movement problem: one command produces more movement than intended.
The pattern matters because the same visible asymmetry can have different causes. A narrower eye during smiling may reflect involuntary contraction around the eye. A mouth corner that seems lower may instead be pulled by neck or lower-face muscles. A face that looks uneven at rest may become more balanced during speech, or the reverse. Treating the most conspicuous feature without examining movement risks weakening the wrong part of the system.
Assessment therefore usually compares rest with a short series of movements: gentle and broad smile, lip pursing, cheek inflation, eye closure, brow raise and speech. Video can be useful because a still photograph may miss the linked movement that drives the concern. The functional question is also important. Difficulty keeping food or liquid in the mouth, eye discomfort, strained speech and social effort may matter more than a millimetre of static symmetry.
Not every post-palsy asymmetry is synkinesis. Persistent weakness without unwanted co-contraction is a different problem. Contracture, eyelid position changes, previous surgery and the natural differences between faces can also contribute. A toxin plan has a clearer rationale when it is tied to a reproducible movement pattern and a stated functional or appearance goal.
A screenshot decision rule
- If an unwanted movement reliably appears when a different movement is attempted, synkinesis is a possible treatment target.
- If the main problem is weakness in a muscle that does not contract, toxin cannot make that muscle work.
- If the target muscle is needed for eye protection, speech, eating or smile support, any weakening must be weighed against that function.
- If the pattern changes with rehabilitation, illness or time, the injection map may need to change too.
What the clinical literature can and cannot establish
Botulinum toxin is widely used in specialist facial palsy practice, and published clinical reports describe improvement in synkinesis, asymmetry and related symptoms for selected patients. The mechanism is credible: reducing overactive muscle activity can reduce the visible and functional effect of unwanted co-contraction.
That should not be confused with a settled answer on the ideal protocol. Much of the literature in facial palsy rehabilitation consists of observational work, case series and practice-based approaches. Such studies can show that outcomes improved after treatment, but they are less able to separate the effect of toxin from rehabilitation, natural adaptation, repeated assessment and patient expectation. They also often involve different causes of palsy, different durations since onset, different muscles and different outcome measures.
The most relevant outcome is not necessarily a standard cosmetic photograph. Facial grading systems, synkinesis scales, video-based movement analysis, patient reports and functional measures may each capture something different. An intervention that improves eye narrowing on smiling may not improve speech, confidence or resting symmetry to the same degree. Conversely, a modest visual change can be valuable if it reduces involuntary eye closure or painful neck pull.
There is also limited high-quality evidence to determine a universal dose, interval or order of muscle targets. This is a setting where a strong claim should be narrow: toxin may improve a defined movement problem temporarily. The evidence is weaker for broad promises about recovery, prevention of all long-term sequelae, or a standardised treatment map applicable to everyone.
A useful evidence question is: which movement was measured, compared with what, for how long, and did the outcome matter to daily function?
How treatment is usually sequenced
Sequencing is not a cosmetic timetable. It follows the stage and pattern of facial recovery. In acute facial weakness, the immediate clinical priorities can include identifying the cause, protecting the eye where closure is impaired, and considering time-sensitive medical treatment where appropriate. Toxin is not a substitute for that assessment. A sudden new facial droop, especially with limb weakness, speech difficulty, severe headache or other neurological symptoms, needs urgent medical evaluation.
Once recovery is established and a stable pattern of unwanted co-contraction is apparent, facial rehabilitation is commonly considered alongside, before or around toxin treatment. Movement retraining aims to improve selective control and reduce compensatory over-recruitment. Toxin may create a temporary window in which an overactive muscle is less dominant, potentially making practice of a desired movement easier. The relationship is plausible, but the contribution of each part cannot be assumed from a single course.
A first toxin session is often best treated as a test of a specific hypothesis. For example: if a particular muscle’s pull is reduced, will eye narrowing during smiling lessen without materially worsening closure or smile function? Conservative initial targeting makes the result easier to interpret. Review should compare the stated target movement, functional effects and unwanted weakness, rather than simply asking whether the face is “more even”.
Further sessions may refine the map, maintain a benefit that fades, or stop if the functional trade-off is not acceptable. Repeated treatment does not prove that recovery has stalled permanently. Nor does a short-lived benefit mean the intervention failed: temporary action is expected from the drug class. The plan should remain responsive to what the face does, not what an initial diagram predicted.
Balancing symmetry against function and adverse effects
In a partially recovered face, a muscle can be both part of the problem and part of a compensatory solution. Weakening it may improve one expression while worsening another. This is particularly relevant around the eye and mouth. Excess reduction of activity around the eye may affect closure or comfort. Around the mouth, it may alter articulation, drinking, lip seal, smile shape or control of food. Lower-face and neck treatment can also change how speech and swallowing feel for some people.
The relevant risks depend on the injection site, dose, baseline facial function and individual anatomy. Effects can include local discomfort, bruising, asymmetry, weakness beyond the intended change and an outcome that feels unfamiliar rather than improved. Rarely, effects beyond the desired area are reported with botulinum toxin products. Product information contains contraindications, warnings and interaction information that need individual clinical consideration.
The NHS advises urgent assessment for signs of stroke, including sudden facial weakness with other neurological symptoms. A person whose facial weakness is new, worsening, painful, associated with a rash near the ear, altered hearing, double vision, swallowing difficulty or other neurological features should not treat it as a routine asymmetry question.
Expectation setting is therefore a safety issue, not a courtesy. The meaningful comparison is usually with the person’s own pre-treatment movement pattern. A symmetrical still image is not a sufficient endpoint if the treatment compromises a function that matters to them. In London, practices working in this area include Dr Harry Clinic in Chiswick, where Dr Harry James offers botulinum toxin treatment for Bell's palsy and facial palsy alongside the cosmetic side of the practice.
How to judge whether a proposed plan is evidence-led
An evidence-led plan does not need to promise certainty. It should make its uncertainty visible and specify what will be tested. Before treatment, the practitioner should be able to describe the unwanted movement, the muscle activity thought to contribute, the functional goal and the potential downside of reducing that activity. “Balance” is too vague unless it is translated into an observable movement.
Photography and video can provide a baseline if used consistently, but they should cover both rest and relevant expressions. A plan aimed at eye-mouth synkinesis should document eye closure during smiling or speech, not only a neutral image. The same movements should be reviewed after treatment. This creates a more useful record than an impressionistic before-and-after comparison.
Questions worth asking include whether facial rehabilitation is part of the plan, what change would count as success, and what would lead to changing or stopping the approach. A cautious plan may begin with fewer targets because it preserves information: it is easier to identify the source of a useful or unwanted result. Adding many injections at once can make attribution difficult.
| Plan element | What a clear answer looks like | Reason it matters |
|---|---|---|
| Target | A named unwanted movement, such as eye narrowing on smile. | Links treatment to a measurable problem. |
| Function | What must not worsen, such as comfortable eye closure or lip seal. | Prevents symmetry being treated as the only outcome. |
| Review | The same movements are reassessed after the expected onset period. | Tests the initial hypothesis rather than relying on memory. |
| Revision | A stated reason to alter, defer or stop future treatment. | Recognises that response is individual and temporary. |
Limits of this evidence position
This page addresses botulinum toxin for synkinesis and asymmetry after facial nerve palsy. It does not diagnose the cause of facial weakness, advise on acute Bell's palsy management, set injection doses, map injection points, or replace an examination by a clinician experienced in facial nerve disorders. It also does not cover surgical reanimation, eyelid surgery, filler, electrical stimulation or general cosmetic toxin treatment.
The discussion applies most directly to people with established, partially recovered facial palsy who have a reproducible unwanted movement pattern. It may not apply to complete flaccid paralysis, rapidly changing weakness, congenital facial difference, movement disorders unrelated to facial nerve injury, or asymmetry caused chiefly by skeletal structure or skin change. Children, pregnancy and breastfeeding, neuromuscular conditions, relevant medicines and prior adverse reactions require individual consideration that cannot be resolved by a general evidence summary.
Finally, a visible result is not the same as nerve recovery. Botulinum toxin can be a useful symptom-management tool within a sequenced plan, particularly when the desired change is specific and the functional trade-off is acceptable. It remains temporary, pattern-dependent and limited by the quality of the underlying evidence.